Product Description
Mechanisms of Action: GABA Modulator,TSPO Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Chile | Germany | India | Ireland | Italy | Lebanon | New Zealand | Pakistan | South Africa | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Canadian Network for Observational Drug Effect Studies, CNODES
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Multiple Sclerosis, Relapsing-Remitting